Close Menu

Precipio

The suit alleges that Precipio is required to pay more than $2 million in debt owed by Transgenomic, which it acquired last year.

The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan. 

The company is offering units consisting of preferred stock and warrants to purchase shares of its common stock.

More than 90 percent of voting Transgenomic shareholders gave the go-ahead to the deal. Upon completion of the merger, the new firm will take on the Precipio name. 

The company will use the funds to complete its merger with Precipio Diagnostics, which is expected to close in the second quarter.

The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.

LifeLabs will have a non-exclusive license to the technology and use it in its mutation enrichment platform for cancer testing.

Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.

JoyingBio will distribute Transgenomic's multiplexed ICE COLD-PCR kits in China and Biotron Healthcare will do the same in India.

The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.

Pages

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.